Apollomics Terminates US Staff, Halts SPARTA Trial
Ticker: APLMW · Form: 6-K · Filed: Aug 28, 2025 · CIK: 1944885
| Field | Detail |
|---|---|
| Company | Apollomics Inc. (APLMW) |
| Form Type | 6-K |
| Filed Date | Aug 28, 2025 |
| Risk Level | high |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bearish |
Sentiment: bearish
Topics: layoffs, cash-crunch, clinical-trial-discontinuation
TL;DR
Apollomics is out of cash, firing everyone including CEO/CFO, and stopping the SPARTA trial.
AI Summary
On August 28, 2025, Apollomics Inc. announced the termination of all U.S. employees, including CEO Dr. Guo-Liang Yu and CFO Dr. Matthew Plunkett, effective August 29, 2025, due to its cash position. The company also plans to discontinue the SPARTA clinical trial.
Why It Matters
This action indicates severe financial distress for Apollomics, potentially leading to the cessation of its operations and the abandonment of its clinical development programs.
Risk Assessment
Risk Level: high — The company is terminating all U.S. employees due to its cash position, signaling imminent operational shutdown and potential bankruptcy.
Key Players & Entities
- Apollomics Inc. (company) — Filing company
- Dr. Guo-Liang Yu (person) — Terminated Chief Executive Officer
- Dr. Matthew Plunkett (person) — Terminated Chief Financial Officer
- August 28, 2025 (date) — Date of announcement
- August 29, 2025 (date) — Effective date of terminations
FAQ
What is the primary reason for the termination of U.S. employees?
The company announced the termination of all U.S. employees due to its cash position.
Who are the key executives terminated?
The terminated executives include Chief Executive Officer Dr. Guo-Liang Yu and Chief Financial Officer Dr. Matthew Plunkett.
When are the employee terminations effective?
The terminations are effective as of August 29, 2025.
What is the status of the SPARTA clinical trial?
Apollomics expects to discontinue all activities related to the SPARTA clinical trial as soon as possible.
What is the filing date of this report?
This Form 6-K report was filed on August 28, 2025.
Filing Stats: 363 words · 1 min read · ~1 pages · Grade level 9.2 · Accepted 2025-08-28 06:30:15
Filing Documents
- d51002d6k.htm (6-K) — 11KB
- d51002dex991.htm (EX-99.1) — 58KB
- d51002dex992.htm (EX-99.2) — 20KB
- g51002dsp1a.jpg (GRAPHIC) — 6KB
- g51002dsp1b.jpg (GRAPHIC) — 9KB
- g51002dsp1c.jpg (GRAPHIC) — 1KB
- g51002dsp1djpg.jpg (GRAPHIC) — 3KB
- g51002g35x18.jpg (GRAPHIC) — 2KB
- g51002g81w91.jpg (GRAPHIC) — 2KB
- 0001193125-25-190310.txt ( ) — 120KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Apollomics Inc. Date: August 28, 2025 By: /s/ Guo-Liang Yu Guo-Liang Yu, Ph.D. Chief Executive Officer